Introduction
The GTPase Rho functions as a binary switch by cycling between the active GTP-bound state and the inactive GDP-bound state. Three classes of regulatory proteins control the guanine nucleotide binding cycle of Rho family GTPases: guanine nucleotide exchange proteins (GEFs) promote the transition from the inactive GDP-bound state to the active GTP-bound conformation; GTPase activating proteins (GAPs) stimulate GTP hydrolysis while guanine nucleotide dissociation inhibitors (GDIs) act to lock the GTPase in either the active or inactive state (Zohn et al., 1998) . Activated GTP bound Rho is able to regulate diverse cellular processes by coupling to multiple biochemical eector signalling pathways. The ®rst biological function for Rho was established in ®broblasts where it is required for the dynamic organization of the actin cytoskeleton and the assembly of associated integrin structures: RhoA regulates the formation of actin stress ®bres and focal adhesions (Ridley and Hall, 1992) . It is now recognized that Rho function extends beyond control of cellular actin structures and can regulate a diverse set of cell responses including regulation of gene transcription and cell cycle progression (Olson et al., 1995; Hill et al., 1995) . In this context, it is essential to note that multiple eectors for activated Rho have been found. Some of the eectors regulate the actin cytoskelton, although many others have quite dierent functions. Activated forms of RhoA or guanine nucleotide exchange proteins for Rho family GTPases synergize strongly with the Raf oncogene in in vitro transformation assays. Moreover, intact Rho signalling has been shown to be important for the transformation of ®broblasts via oncogenic Ras (Olson et al., 1998; Prendergast et al., 1995; Qiu et al., 1995) . This function of Rho in cellular transformation has recently been shown to be mediated by the Rho eector ROCK-1, a serine/threonine kinase (Sahai et al., 1999) . ROCK-1 also participates in Ras mediated transformation in vitro although interestingly, it is clear that not all cell transformation is dependent on ROCK-1 function; inhibitors of this kinase block Ras mediated transformation but not transformation induced by expression of v-src (Sahai et al., 1999) . Nevertheless, the involvement of Rho in cell transformation in vitro has prompted much interest in the idea Rho GTPases may be useful targets for anti-tumour therapy (Itoh et al., 1999) .
Immunological interest in Rho GTPases stems from genetic evidence demonstrating that these molecules play a critical role in regulating cell survival, proliferation and dierentiation during lymphocyte development. Moreover, in biochemical studies, regulators of Rho GTPases have emerged as important components of signal transduction pathways used by antigen, costimulatory, cytokine and chemokine receptors to regulate the immune response (Henning and Cantrell, 1998) . T lymphocyte development occurs within the thymus and is controlled by a complex array of intracellular signal transduction pathways initiated by antigen receptors and cytokine receptors (Owen and Venkitaraman, 1996) . In order to explore the role of Rho in the thymus, we have used the proximal p56lck promoter to drive thymocyte-speci®c expression of the bacterial enzyme C3-transferase from Clostridium botulinum which selectively ADP-ribosylates Rho within its eector-binding domain and thereby abolishes its biological function (Aktories et al., 1988; Rubin et al., 1988) . C3-transferase is an invaluable tool for the study on Rho function, and studies of C3 transgenic mice have shown that T-lymphocyte speci®c Rho inactivation severely impairs the generation of normal numbers of thymocytes and peripheral T cells (Gallandrini et al., 1997; Henning et al., 1997) . The main defect caused by lack of Rho function in the lck-C3 transgenic mice is a survival failure in early thymocyte progenitors which are able to exit G1 and enter the replicative phases of the cell cycle but undergo apoptosis in the absence of Rho function. There is also a second problem in lck-C3 transgenic mice: late pre-T cells show a partial block in cell cycle progression that impairs the generation of subsequent thymocyte subsets.
Here we report a further defect in the lck-C3 mice; namely the development of thymic lymphoblastic lymphomas between 4 and 8 months of age. Previously, the speci®c role of Rho in tumour development has only been studied in cell lines in vitro where it has been identi®ed as a mediator of cell transformation (Prendergast et al., 1995; Qiu et al., 1995) . Our studies reveal that loss of Rho function in the thymus results in rapid onset of aggressive thymic lymphoma. Accordingly, our in vivo analysis of Rho function provides important new insight into the biological role of the small GTPase Rho in lymphocytes and suggests that it has a previously unsuspected role in suppressing maligant transformation.
Results

lck-C3 transgenic mice develop thymic lymphomas
Maintenance of two independently derived lck-C3 transgenic lines revealed that although initially healthy, mice were dying prematurely in comparison with nontransgenic littermates. Eighty per cent of transgenic mice (n=70) died between 4 and 8 months of age, with no transgenic mice from either line surviving beyond 12 months. The normal life span of wild-type C57/BL6 mice is at least 24 months in a speci®c pathogen free environment. Post-mortem examination indicated that the deaths occurring in the lck-C3 mice were a result of compression of the heart and lungs by a grossly enlarged thymus ( Figure 1a, top panel) . The mean cell number of the enlarged thymus was 9610 8 in comparison with 5610 7 observed in age matched littermate controls. Histological analysis showed that the characteristic structures of the thymic medulla and cortex were no longer evident (Figure 1b, top panel) .
Further examination of the lck-C3 transgenic mice revealed enlarged secondary lymphoid organs, including the spleen (Figure 1a , centre panel), lymph nodes ( Figure 1b , bottom panel), and in most cases the liver. In the spleens of the lck-C3 mice, in®ltration of cells indistinguishable from the lymphoblasts of the thymic lymphoma (as assessed by morphology and cell surface markers) almost entirely replaced the normal white and red pulp regions ( Figure 1b , centre panel). In the liver, similar in®ltration of lymphoblasts was seen throughout the organ, most notably around blood vessels ( Figure 1b , bottom panel). In no instance were these secondary manifestations observed in the absence of an enlarged thymus. This observation, coupled with morphological and cell surface marker analysis, strongly suggests that cells in®ltrating peripheral organs originated from the thymic lymphoma.
Thymic lymphomas are of T cell origin
The pathology of the dead mice diagnosed thymic lymphoma. Con®rmation of this diagnosis came from ow cytometric analysis of thymic tumours from the two independently derived transgenic lines (1222D and 1222C) which revealed the cells to express Thy-1 and the T cell antigen receptor/CD3 complex. The T cell origin of the tumours was also con®rmed by the fact that CD4 and/or CD8 (T cell co-receptors for MHC molecules) were co-expressed on all tumours analysed. Representative CD4 and CD8 pro®les of tumours The other CD4/8 pro®le seen in the tumours (nine out of 16) exhibited intermediate levels of CD8, low levels of CD4 and again intermediate levels of CD3 analogous to those seen on mature thymocytes. FACS analysis of lymph nodes, spleen and bone marrow in tumour bearing mice showed that these organs were composed almost entirely of cells phenotypically identical to those observed in the thymic tumour; an indication of the aggressive recirculating nature of the tumour derived cells described above (data not shown). Cells isolated from lck-C3 derived thymic lymphomas were analysed for expression of various T cell activation markers including CD25, CD69 and CD62L. The thymic lymphomas did not express CD69 or CD62L but did express CD25; the alpha subunit of the Interleukin 2 receptor. Typically 5% of thymocytes express CD25 whereas this molecule was expressed on all lymphoma cells. Figure 3a shows the elevated levels of CD25 present of the surface of cells isolated from the lymphomas compared to those from an age-matched wild-type thymus.
Further analysis revealed the lymphoma cells to be blastoid and much larger than quiescent thymocytes.
Figure 2 Flow cytometric analysis of thymocytes isolated from wild-type, pre-tumour lck-C3 and lck-C3 mice exhibiting thymic lymphomas stained for surface expression of CD4 and CD8 co-receptors. 1222C and 1222D represent two independently-derived transgenic lines These cells were not particularly abnormal in size, rather their size was comparable to the size of normal splenic derived lymphoblasts (Figure 3b ). The cells also showed a DNA staining pro®le typical of normal lymphoblasts in exponential growth, with 2 n, intermediate or 4 n DNA content. No lymphoma cells were polyploid (Figure 3c ).
Normal thymocytes from lck-C3 transgenic mice are devoid of functional Rho GTPase because of expression of Clostridium Botulinum C3 transferase which ribosylates Rho thereby inactivating its function . Expression of the C3 transgene in tumour samples was analysed by RT ± PCR. In four independent tumour samples endogenous p56lck was Figure 3 Flow cytometric analysis of the lymphoma cell population. (a) Analysis of surface CD25 expression on wild-type and lck-C3 lymphoma cells. (b) Flow cytometric forward scatter analysis of thymocytes isolated from thymic lymphoma compared with those of an age-matched wild-type mouse and wild-type T-blasts generated by stimulation with ConA (5 ug/ml), PdBu (50 ng/ml) and IL-2 (20 ng/ml) for 72 h. (c) Cell cycle analysis of cells isolated from age-matched wild-type and lck-C3 mice exhibiting thymic lymphoma. Cells were ®xed and permeabilized in 70% ethanol, stained with propidium iodide and analysed on a FACS Calibur expressed and expression of the lck-C3 transgene was maintained (Figure 4) . lck-C3 transgenic mice exhibit a median survival age of 6 months and develop monoclonal tumours
The data in Figure 5 show a survival curve of lck-C3 transgenic mice. All the lck-C3 mice exhibited the development of thymic lymphomas over the period of study. The ®rst thymic tumours are seen in mice at 3 months of age, with the median age for tumour development being 6 months. The incidence of thymic lymphoma in the wild-type C57BL/6 strain is 0 ± 2% in the ®rst 12 months of age (Bronson, 1990) . The cell surface expression of CD8 and CD4 on tumour cells is indicated (where determined).
Having established that the tumours were of T cell origin we wished to determine if they were polyclonal or monoclonal in nature. All tumour cells expressed the T cell antigen receptor complex which normally comprises TCR-a and b subunits coupled to the invariant CD3 antigen complex. A clonal T cell population would express a single TCR-b chain whereas polyclonal populations would show usage of multiple vbs. In C57BL/6 mice, the most commonly used vbs are vb8, typically expressed by 20% of the T cell population, and vb11, comprising approximately 5% of the population. We routinely performed vb subgroup staining to investigate the TCR repertoire of normal and tumour derived T lymphocytes. The pre-tumour lck-C3 mice expressed vb8 and vb11 ratios similar to WT C57BL/6 mice. Assuming transformation was a rare event, occurring within a single cell and without bias, we would expect approximately 20% of the tumours to be vb8 positive and 5% to be vb11 positive. Interestingly, three out of the 16 tumours analysed (18%) exclusively expressed vb8, while one out of 16 (6.25%) exclusively expressed vb11. The remaining 12 out of 16 tumours analysed were negative for both vb8 and vb11, demonstrating that the normal repertoire of vb expression was absent and thus transformation was not occurring simultaneously throughout the whole ab T cell population. Representative pro®les are illustrated in Figure 6 . These phenotypes are not consistent with a polyclonal origin of the thymic lymphomas and strongly indicate that the tumours are monoclonal in nature, arising from a single rare transformation event.
Discussion
We have used the proximal p56lck promoter to drive thymocyte-speci®c expression of the bacterial enzyme C3-transferase which selectively and effi- Figure 4 Expression of C3-transgene, p56lck, and HPRT mRNA in tumour tissue. Cells were isolated from four typical lck-C3 thymic lymphomas along with a wild-type thymus, total RNA prepared and RT ± PCR performed to detect expression of mRNA speci®c for C3-transgene, endogenous p56lck, and HPRT Figure 5 Latency of thymic lymphoma development in lck-C3 transgenic mice maintained in a speci®c pathogen-free environment. Percentage survival of C57BL/6 (*) and transgenic mice (^) is plotted versus age of detection (in days). Where determined, the CD4/CD8 phenotype analysed by¯ow cytometry is indicated by DP (CD4/CD8 double positive) or IDP (CD4/CD8 intermediate double positive) ciently inhibits the function of the Rho GTPase. The initial defect caused by lack of Rho function in the lck-C3 transgenic mice is increased rates of apoptosis in early thymocyte progenitors which are able to exit G1 and enter the replicative phases of the cell cycle but undergo apoptosis in the absence of Rho function. There is also a second defect in lck-C3 transgenic mice: late pre-T cells show a partial block in cell cycle progression that impairs the generation of subsequent thymocyte subsets. Here we report a further defect in the lck-C3 mice; strikingly the mice go on to develop aggressive thymic lymphoma. We believe this demonstrates a previously unsuspected role for Rho in the suppression of malignant transformation. What is not clear is whether the tumours develop as a direct consequence of loss of Rho function or that loss of Rho function causes selection of a subset of cells with compensatory changes that predipose them to cellular transformation. However, it should be emphasised that perturbation of thymocyte development in itself does not a priori lead to tumour development. Blocks in thymocyte development in transgenic mice that show thymocyte survival defects comparable to those seen in young lck-C3 mice (for example, those expressing dominant negative Myb, or null for bcl-x expression (Badiani et al., 1994; Ma et al., 1995) ) do not develop lymphoma. Furthermore, loss of the function of other GTPases such as Ras or Rac also perturbs thymic development but does not result in predisposition to thymic lymphoma. It should also be noted that although the lck-C3 mice exhibit reduced numbers of peripheral T cells and are thus immunocompromised, there are many examples of mice with immunode®ciencies which do not go on to develop lymphomas (e.g. Vav ). Typically, transgenic mice that develop thymic lymphomas are either those that express activated oncogenes such as lck, myb, and PIM1 in the thymus (Abraham et al., 1991; Badiani et al., 1996; van Lohuizen et al., 1989) , or those with deleted tumour suppressor genes (e.g. p53) (Donehower et al., 1992) .
All tumours in the lck-C3 mice were of T cell origin and expressed a mature TCR complex. The observation that the tumour-derived cell population lacked heterogeneity of vb expression (i.e. expressed one vb rather than the full repertoire) indicates that these Figure 6 Flow cytometric analysis of vb subgroup expression on CD3 positive thymocytes isolated from an age-matched C57BL/6 wild-type (WT) and three representative lck-C3 mice exhibiting thymic lymphomas (T1, T2, T3). Displayed are the vb8 and vb11 histograms of CD3 positive cells. Each histogram is overlayed with the same pro®le from that of a wild-type mouse analysed on the same day tumours have arisen from a single cell and are thus monoclonal rather than polyclonal tumours. From the monoclonality of the tumours in the lck-C3 transgenic mice we would propose that loss of Rho function is not sucient for direct transformation of T cells; rather lack of Rho function predisposes cells to further rare transforming events. This is not unusual; a single genetic insult never directly transforms cells and multiple genetic lesions are required for the development of malignancy (Hunter, 1991) . The thymic lymphomas in the lck-C3 mice express some phenotypic markers typically associated with thymocytes; notably the coexpression of CD4/CD8 molecules. Prior to the onset of the lymphomas most thymocytes in lck-C3 animals die as early progenitors so that CD4/8 DP thymocytes are generated at greatly reduced numbers (5 ± 10% of normal). The phenotype of the tumours that develop in the lck-C3 mice indicate that they arise from the few CD4/CD8 DP thymocytes that are able to escape the major survival defect that occurs in early Rho 7 T cell progenitors. These escaping cells retain expression of the C3 transferase and thus lack functional Rho, but may have been selected in some way to compensate for loss of Rho function in earlier progenitor cells. As discussed earlier, one possibility is that the selection of cells to compensate for loss of Rho function predisposes the cells to transformation.
Genetic approaches to molecular function in vivo can lead to the discovery of roles for cellular proteins that were unsuspected from those elucidated by in vitro experiments. Previously, the speci®c role of Rho in tumour development has only been studied in cell lines where it has been identi®ed as a mediator of cell transformation. The present study is the ®rst to experimentally examine Rho function in vivo. The observation that loss of Rho function in the thymus results in rapid onset of aggressive thymic lymphoma is striking and inescapable. The present data reveals that it may be interesting to pursue whether loss of Rho function through mutagenesis/translocation of Rho regulatory proteins or their eectors is associated with human leukaemias or lymphoma. Furthermore, inhibiting Rho function has been suggested as a therapeutic strategy for treatment of Ras-transformed tumours (Olson et al., 1998; Sahai et al., 1999) . This idea is based on the fact that strategies to inhibit Rho function in cell lines result in loss of in vitro transforming capacity. The generation of lck-C3 transgenic mice represents the ®rst experimental approach to eliminate Rho function in vivo and here loss of Rho function is causally related to promotion of cell transformation capability. Any in vivo attempt to block Rho function in vivo would thus need to be used with caution; Rho may function as an oncogene in ®broblast cell lines but in lymphocytes loss of Rho function is associated with tumour development.
Materials and methods
Generation of transgenic mice
A puri®ed 6.2 kb NotI fragment (2 ng/ul) containing the lck ± C3 ± hGH transgene was injected into the pronuclei of day 1 F1 mouse zygotes (C57BL/6J X CBA/J). Embryos were transferred into pseudo-pregnant F1 foster mice, which gave birth to litters of 5 ± 10 mice 20 days later. Stable lines were generated by backcrossing transgene-carrying founder mice with C57BL/6J mice.
PCR
Transgene carrying mice were identi®ed by polymerase chain reaction employing transgene speci®c primers: G9112 (GCCACCATGGAGCAGAAGCTGATCTCCGG) and C3NT (CTGATTTGCTTAGTCCATAC) or MO142 (GCGCTTACCTGTAGGCATTGC) and C3CT (GGGCA-CAGCTATCAATCC). Genomic DNA was puri®ed from mouse ear punches and used as template for 35 cycles of polymerase chain reaction (578C annealing, 728C elongation, 958C denaturation).
RT ± PCR
Tumour samples were dissolved in 500 ml RNazol (Cinna Scienti®c). Total RNA was extracted according to the manufacturer's protocol and subjected to DNase treatment. The reverse transcriptase (RT) reaction was performed using random hexamer primers, and the cDNA obtained was used as template for PCR reactions employing primer speci®c for hypoxanthinephosphoribosyltransferase (5'-CACAGGAC-TAGAAC ACCTGC-3' and 5'-GCTGGTGAAAAGGACC-TCT-3'), p56lck (5'-GCCCATCCGGAATG GCTCTG-3' and 5'-CGCCACGAAGTTGAAGGG-3') and C3 transferase (5'-GAGGGAACCCAGTCAGTCAGGAGC-3' and 5'-CTGATTTGCTTAGTCCATAC-3'). PCR reactions were performed in 20 mM ammonium sulphate, 75 mM Tris-HCl (pH 9.0), 0.01% Tween 20, 1.2 mM MgCl 2 , 200 mM dNTP, 0.5 U Taq DNA polymerase, and 1 mM of each primer. DNA was ampli®ed for 35 cycles at an annealing temperature of 578C. PCR products were separated in 2% agarose gels and stained with ethidium bromide.
Histological analysis
Tissues for histology were frozen in liquid N 2 , sectioned and stained with haematoxylin and eosin.
Cell preparation
Thymi and spleens were obtained by dissection from mice bearing thymic lymphomas or age matched controls. Tissue was disaggregated by pressing through a 70 mm nylon mesh ®lter to obtain a single cell suspension. Bone marrow was obtained by dissecting out the femur and¯ushing with media using a 23-gauge needle before passing through a 70 mm nylon mesh ®lter as above.
Flow cytometric analysis
Antibodies (Pharmingen) were obtained conjugated to either uorescein isothiocyanate (FITC), phycoerythrin (PE) or biotin. Biotinylated antibodies were revealed using streptavidin-TRICOLOR (Caltag). Thymocytes or splenocytes were stained for surface expression of CD8 (53-5.8), CD4 (RM4-5), CD3e (145-2C11), abTCR (b-chain, H57-597), B220 (CD45R, RA3-6B2), Vb8 (F23.1), Vb11 (RR3-15) and Thy1.2 (53-2.1). Cells were stained with saturating concentrations of antibody at 48C for 20 min at 2610 6 cells per sample in a 96 well V-bottom shaped microtiter well plate in 100 ml phosphate buered saline containing 1% bovine serum albumin. Cells were washed with this buer between incubations and prior to analysis on a FACS Calibur (Becton Dickinson). Events were collected and stored ungated in list-mode using CellQuest software. Live cells were gated according to their FSC and SSC pro®les and data were analysed using CellQuest software.
